Gilead's Veklury shows 'no antiviral effects' against COVID-19 in small WHO study

Veklury has become routine treatment for severe COVID-19 patients in the U.S., spurring significant sales for Gilead Sciences. Experts have often debated data from the drug’s clinical trials, and now a small study adds points to the arguments voiced by skeptics.